Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/16—Amides, e.g. hydroxamic acids
  • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/16—Amides, e.g. hydroxamic acids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/275—Nitriles; Isonitriles
  • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents

Definitions

• Drug resistant tumors are characterized by a resumption of their growth and/or reappearance after having seemingly gone into remission, despite the administration of increased dosages of the anti-cancer drug.
• Compound (1) had an IC 50 of 0.005, 0.05 and 0.01 ⁇ M against the multi-drug resistant cell lines MES-SA/DX5, HL-60/TX1000 and Bowes/OV2, respectively (see Example 15).
• the IC 50 for the anticancer drugs taxol and vincristine was two to three orders of magnitude larger for the same cell lines (see Example 15).
• the structure of Compound (1) is shown below:
• the IC 50 for bis[thio-hydrazide amide] Compounds (2)-(18) ranged from 0.05 to 0.005 ⁇ M against MES-SA/DX5 (see Example 16) .
• the structures of Compounds (2)-(18) are provided in Figure 1.
• the size of multi-drug resistant MES-SA/DX5 tumors in nude mice treated with bis[thio-hydrazide amide] Compound (16) was significantly reduced compared with tumors in mice treated only with vehicle (see Example 17).
• the structure of Compound (16) is shown below:
• One embodiment of the present invention is a method of treating a subject with a multi-drug resistant cancer.
• the method comprises administering to the subject an effective amount of a compound represented by Structural Formula (I):
• Y is a covalent bond or -C(R 7 R 8 )-.
• R R 4 are independently -H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group, or K ⁇ and R 3 taken together with the carbon and nitrogen atoms to which they are bonded, and/or R 2 and R 4 taken together with the carbon and nitrogen atoms to which they are bonded, form a non-aromatic heterocyclic ring optionally fused to an aromatic ring.
• R j and R 2 are the same and R 3 and R 4 are the same.
• R 5 -R 6 are independently -H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group.
• R 5 and R 6 are the same.
• R 7 and R 8 are each independently -H, an aliphatic or substituted aliphatic group, or R 7 is -H and R 8 is a substituted or unsubstituted aryl group, or, R 7 and R 8 taken together, are a C2-C6 substituted or unsubstituted alkylene group.
• Another embodiment of the present invention is a method of treating a subject with cancer.
• the method comprising administering to the subject an effective amount of a compound represented by Structural Formula (I).
• the compound represented by Structural Formula (I) is administered as a monotherapy (i.e., as the only anti-cancer drug administered to the subject).
• a second anti-cancer agent is co- administered to the subject, provided that the second anti-cancer agent is other than taxol or an analog of taxol.
• the subject is a mouse, then the compound is other than:
• the method is commonly used with subjects other than mice.
• the subject is a human subject.
• the disclosed method can often be used to treat cancers, including cancers that have become multi-drug resistant.
• the disclosed methods can often be used to treat cancers where other drug regimens have either failed or become ineffective.
• the compounds used in the method are relatively non-toxic, they cause minimal side effects and can used at relatively high doses.
• Figures 1A-1D are a list of structures of Compounds (2)-(18) that are exemplified with the disclosed method.
• Figure 2 is a graph showing the average tumor size in nude mice (CD-I nu/nu) over time after having been treated with vehicle (•) or Compound (16) ( ⁇ ).
• the tumor volume is in mm 3 and the time is in days after having begun treatment.
• the tumors are from the multi-drug resistant human uterine sarcoma MES-SA/DX5.
• Figure 3 is a graph showing the average tumor volume in milliliters over time (in days) in nude mice (CD-I nu nu) treated with vehicle (•) ; Epothilone D (5 mg/kg) ( ⁇ ); and Compound (1) (50 mg/kg) and Epothilone(5 mg/kg) (o).
• the tumors were generated from the human breast tumor cell line MDA-435.
• Figure 4 is a graph showing the average percent weight change in nude mice (CD-I nu/nu) over time after having been treated with vehicle (•); Epothilone D (5 mg/kg) ( ⁇ ); and Compound (1) (50 mg/kg) and Epothilone(5 mg/kg) (o). The mice were being treated for tumors generated tumors generated from the human breast tumor cell line MDA-435.
• R r R 6 in Structural Formula (II) are as described in Structural Formula (I).
• Ar is a substituted or unsubstituted arylene group.
• Ar is a nitrogen-containing heteroarylene group. Examples are shown below:
• Ring A is substituted or unsubstituted.
• Y in Structural Formula (I) is a covalent bond, a substituted or unsubstituted straight chained hydrocarbyl group or a phenylene group.
• R 7 and R 8 are as described for Structural Formula (I). Even more preferably, Y is a covalent bond or -C(R 7 R 8 )-.
• Y in Structural Formula (I) is a covalent bond or -C(R 7 R 8 )- and the compound used in the method of the present invention is represented by Structural Formula (III):
• R r R 6 are as described for Structural Formula (I).
• Y' is a covalent bond or -C(R 7 R 8 )-; and R 7 and R 8 can be the same or different and are: i) each independently -H, an aliphatic or substituted aliphatic group (preferably alkyl, more preferably methyl); ii) R 7 is -H and R 8 is a substituted or unsubstituted aliphatic group (preferably alkyl, more preferably methyl) or a substituted or unsubstituted aryl group (preferably thienyl, substituted thienyl, phenyl substituted phenyl, benzyl or substituted benzyl); or iii) R 7 and R 8 taken together, are a C2-C6 substituted or unsubstituted alkylene group (preferably propylene or butylene).
• the compound used in the method of the present invention is represented by Structural Formula (IV):
• Y' is a covalent bond or -C(R 7 R 8 )- and Ri-R 4 and R 7 -R 8 are as described for Structural Formula (I).
• R x and R 2 are each a substituted or unsubstituted aryl group; R 3 and R 4 are each a substituted or unsubstituted aliphatic group; R 7 is -H; and R 8 is -H, an aliphatic or substituted aliphatic group.
• R ⁇ and R 2 are each a substituted or unsubstituted aryl group; R 3 and R 4 are each an alkyl group; and R 7 is -H and R 8 is -H or methyl.
• R ! and R 2 are each a substituted or unsubstituted phenyl group; R 3 and R 4 are each methyl or ethyl; and R 7 is -H and R 8 is -H or methyl.
• Suitable substituents for an aryl group represented by R t and R 2 and an aliphatic group represented by R 3 , R and R 8 are as described below for aryl and aliphatic groups.
• R ] and R 2 are both phenyl or substituted phenyl, R 3 and R 4 are both methyl, ethyl, phenyl, or thienyl, and R 7 and R 8 are as described in the first example of a compound represented by Structural Formula (IV).
• R, and R 2 are both phenyl or substituted phenyl and R 3 and R 4 are both methyl, ethyl, phenyl, or thienyl, then preferably R 7 and R 8 , taken together, are propylene or butylene.
• Rj and R 2 are both an aliphatic group or a substituted aliphatic group (preferably substituted or unsubstituted alkyl group, including a substituted or unsubstituted cycloalkyl group such as a substituted or unsubstituted cyclopropyl group); R 3 and R 4 are both an aryl group or a substituted aryl group, and R 7 and R 8 are as described the first example of a compound represented by Structural Formula (IV).
• Rj and R 2 are both substituted or unsubstituted aliphatic groups
• R 3 and R 4 are both a lower alkyl group or a substituted lower alkyl group
• R 7 and R 8 are as described in the first example of a compound represented by Structural Formula (IV); preferably, R and R 2 are both substituted or unsubstituted alkyl groups (more preferably substituted or unsubstituted cycloalkyl groups),
• R 3 and R 4 are both -H, methyl or ethyl, R 7 is -H and R 8 is -H or methyl.
• Rj and R 2 are both C3-C8 cycloalkyl or substituted C3-C8 cycloalkyl and R 3 and R 4 are both methyl, ethyl, phenyl, or thienyl, and R 7 and R 8 are as described the first example of a compound represented by Structural Formula (IV) (preferably, R 7 and R 8 are: 1) both methyl; 2) taken together, are propylene or butylene; or 3) R 7 is -H and R 8 is lower alkyl, thienyl, phenyl or benzyl).
• Structural Formula (IV) preferably, R 7 and R 8 are: 1) both methyl; 2) taken together, are propylene or butylene; or 3) R 7 is -H and R 8 is lower alkyl, thienyl, phenyl or benzyl).
• R and R 2 are both a lower alkyl group or a substituted lower alkyl group
• R 3 and R 4 are both methyl, ethyl or phenyl
• R 7 and R 8 are as described the first example of a compound represented by Structural Formula (IV).
• R x and R 2 are both phenyl; R 3 and R 4 are both methyl; R 7 is -H, and R 8 is ethyl; R j and R 2 are both phenyl; R 3 and R 4 are both phenyl, and R 7 and R 8 are both methyl; Rj and R 2 are both 2-thienyl; R 3 and R 4 are both phenyl, and R 7 and R 8 are both methyl; R ⁇ and R 2 are both 4-cyanophenyl; R 3 and R 4 are both methyl; R 7 is -H, and R 8 is methyl; Rj and R 2 are both phenyl; R 3 and R 4 are both methyl; R 7 is -H, and R g is methyl; Rj and R 2 are both phenyl; R 3 and R 4 are both methyl; R 7 is -H, and R 8 is benzyl; R 1 and R 2 are both phenyl; R 3 and R 4 are both methyl; R 7 is -H
• R 2 are both 1-methylcyclopropyl; R 3 and R 4 are both methyl; R 7 is methyl and R 8 is -H; R t and R 2 are both 1-methylcyclopropyl; R 3 and R 4 are both methyl; R 7 is ethyl and R 8 is -H; Rj and R 2 are both 1 - methylcyclopropyl; R 3 and R 4 are both methyl; R 7 is n-propyl and R 8 is -H; R x and R 2 are both 1 —methylcyclopropyl; R 3 and R 4 are both methyl; R 7 and R 8 are both methyl; R t and R 2 are both 1-methylcyclopropyl; R 3 and R 4 are both ethyl; R 7 and R 8 are both - H; R j and R 2 are both 1-methylcyclopropyl; R 3 is methyl, and R is ethyl; R 7 and R 8 are both -H; R x and R 2 are both 2-methylcyclo
• R 2 are both cyclohexyl; R 3 and R 4 are both methyl; R 7 and R 8 are both -H; R ⁇ and R 2 are both cyclohexyl; R 3 and R 4 are both phenyl; R 7 and R 8 are both -H; R j and R 2 are both methyl; R 3 and R 4 are both methyl; R 7 and R 8 are both -H; R and R 2 are both methyl; R 3 and R 4 are both t-butyl; R 7 and R 8 are both -H; R x and R 2 are both methyl; R 3 and R 4 are both phenyl; R 7 and R 8 are both -H; R !
• R 2 are both t-butyl; R 3 and R 4 are both methyl; R 7 and R 8 are both -H; R t and R 2 are ethyl; R 3 and R 4 are both methyl; R 7 and R 8 are both -H; R and R 2 are both «-propyl; R 3 and R 4 are both methyl; R 7 and R 8 are both -H.
• Y in these examples is preferably -C(R 7 R 8 )-.
• the compound used in the method of the present invention is represented by Structural Formula (V):
• R r R 4 in Structural Formula (V) are as described in Structural Formula (I).
• Y" is a covalent bond or -CH 2 -.
• R 3 and R 4 are both a substituted or unsubstituted aliphatic group, preferably both a substituted or unsubstituted alkyl group and more preferably both a methyl or ethyl group .
• R 3 and R 4 in Structural Formula (V) are both a substituted or unsubstituted aliphatic group
• R and R 2 are preferably both a substituted or unsubstituted aliphatic group (e.g., a substituted or unsubstituted alkyl group and preferably a C3-C8 substituted or unsubstituted cycloalkyl group such as a substituted or unsubstituted cyclopropyl group); or 2) R x and R 2 are preferably both a substituted or unsubstituted aryl group (e.g., a substituted or unsubstituted heteroaryl group or a substituted or unsubstituted phenyl group; or 3) R j is preferably a substituted or unsubstituted aliphatic group (preferably a substituted or unsubstituted cycloalkyl group such as a substituted or unsubstituted cycl
• R 3 and R 4 are both a substituted or unsubstituted heteroaryl group.
• R 3 and R 4 in Structural Formula (V) are both a substituted or unsubstituted heteroaryl group, then: 1) R x and R 2 are preferably both a substituted or unsubstituted phenyl group; 2) R t and R 2 are preferably both a substituted or unsubstituted heteroaryl group; 3) Ri and R 2 are preferably both a substituted or unsubstituted aliphatic group (preferably a substituted or unsubstituted alkyl group and more preferably a substituted or unsubstituted cycloalkyl group such as a substituted or unsubstituted cyclopropyl group); or 4) R x is preferably a substituted or unsubstituted aliphatic group (preferably a substituted or unsubstituted or unsubstituted aliphatic group (preferably a
• R 3 and R 4 are both a substituted or unsubstituted phenyl group.
• R 3 and R 4 in Structural Formula (V) are both a substituted or unsubstituted phenyl group, then: 1) R j and R 2 are preferably both a substituted or unsubstituted phenyl group; 2) R x and R 2 are preferably both a substituted or unsubstituted heteroaryl group; 3) R x and R 2 are both a substituted or unsubstituted aliphatic group (preferably a substituted or unsubstituted alkyl group and more preferably a C3-C8 substituted or unsubstituted cyclic aliphatic group such as a substituted or unsubstituted cyclopropyl group); or 4) Rj is a substituted or unsubstituted aliphatic group (preferably a substituted or
• R t and R 2 are both a substituted or unsubstituted aryl group (e.g., a substituted or unsubstituted heteroaryl group or a substituted or unsubstituted phenyl group). More preferably, R 3 and R 4 are both methyl.
• R x and R 2 are both a substituted or unsubstituted aliphatic group, preferably both a substituted or unsubstituted alkyl group, including a C3-C8 cycloalkyl group optionally substituted with at least one alkyl group (e.g., methyl, ethyl, n-propyl, n- butyl, n-pentyl, cyclopropyl, 1-methylcyclopropyl, 2-methylcyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl).
• alkyl group e.g., methyl, ethyl, n-propyl, n- butyl, n-pentyl, cyclopropyl, 1-methylcyclopropyl, 2-methylcyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
• R 3 and R 4 are preferably both: 1) a substituted or unsubstituted aryl group (e.g., a substituted or unsubstituted heteroaryl group or a substituted or unsubstituted phenyl group); or 2) a substituted or unsubstituted aliphatic group (preferably a substituted or unsubstituted alkyl group).
• R x and R 2 are both a substituted or unsubstituted cycloalkyl group, preferably both a substituted or unsubstituted cyclopropyl alkyl group and R 3 and R 4 are as described for Structural Formula (I).
• R x and R 2 are both a substituted or unsubstituted cycloalkyl group, preferably both a substituted or unsubstituted cyclopropyl alkyl group and R 3 and R 4 are as described for Structural Formula (I).
• R j is a substituted or unsubstituted aliphatic group and R 2 is a substituted or insubstituted aryl group and R 3 and R 4 are as described for Structural Formula (I).
• R x and R 2 are both phenyl, and R 3 and R 4 are both o-CH 3 -phenyl; R x and R 2 are both o-CH 3 C(O)O-phenyl, and R 3 and R 4 are phenyl; R x and R 2 are both phenyl, and R 3 and R 4 are both methyl; R !
• R 2 are both phenyl, and R 3 and R 4 are both ethyl; R j and R 2 are both phenyl, and R 3 and R 4 are both n-propyl; R x and R 2 are both/»-cyanophenyl, and R 3 and R 4 are both methyl; Ri and R 2 are bothj?-nitro phenyl, and R 3 and R 4 are both methyl; R x and R 2 are both 2,5-dimethoxyphenyl, and R 3 and R 4 are both methyl; R j and R 2 are both phenyl, and R 3 and R 4 are both n-butyl; Rj and R 2 are both ⁇ -chlorophenyl, and R 3 and R 4 are both methyl; R x and R 2 are both 3-nitrophenyl, and R 3 and R 4 are both methyl; Rj and R 2 are both 3-cyanophenyl, and R 3 and R 4 are both methyl; R x and R 2 are both 3 -fluoroph
• R 2 are both phenyl, and R 3 and R 4 are both 2-ethylphenyl; R x and R 2 are both 2- methyl-5-pyridyl, and R 3 and R 4 are both methyl; or R x is phenyl; R 2 is 2,5- dimethoxyphenyl, and R 3 and R 4 are both methyl; R j and R 2 are both methyl, and R 3 and R 4 are both -CF 3 -phenyl; R x and R 2 are both methyl, and R 3 and R 4 are both o- CH 3 -phenyl; R ! and R 2 are both -CH 2 ) 3 COOH;and R 3 and R 4 are both phenyl; R x and R 2 are both represented by the following structural formula:
• R 3 and R 4 are both phenyl;
• R x and R 2 are both n-butyl, and R 3 and R 4 are both phenyl;
• R x and R 2 are both n-pentyl, R 3 and R 4 are both phenyl;
• R x and R 2 are both methyl, and R 3 and R 4 are both 2-pyridyl;
• R x and R 2 are both cyclohexyl, and R 3 and R 4 are both phenyl;
• R x and R 2 are both methyl, and R 3 and R 4 are both 2-ethylphenyl;
• Rj and R 2 are both methyl, and R 3 and R 4 are both 2,6-dichlorophenyl;
• R,-R 4 are all methyl;
• R x and R 2 are both ethyl, and R 3 and R
• Y the compound used in the method of the present invention is represented by Structural Formula (VI):
• R j -R 6 in Structural Formula (VI) are as described for Structural Formula (I).
• Y" is a covalent bond or -CH 2 -.
• R 5 and R 6 are both an alkyl group (preferably methyl) or a phenyl group.
• R x and R 2 are preferably both phenyl or substituted phenyl and R 3 and R 4 are preferably both an alkyl group.
• R 5 and R 6 are both an alkyl group (preferably methyl) or a phenyl group.
• R x and R 2 are preferably both alkyl or substituted alkyl and R 3 and R 4 are preferably both phenyl or substituted phenyl.
• R x and R 2 are both an alkyl group or a substituted alkyl group and R 3 and R 4 are both alkyl or substituted alkyl.
• R x and R 2 are both phenyl, R 3 and R 4 are both phenyl, R 5 and R 6 are both methyl, and R 7 and R 8 are both -H;
• R x and R 2 are both phenyl, R 3 and R 4 are both phenyl, R 5 and R 6 are both n-hexyl, and R 7 and R 8 are both -H;
• R x and R 2 are both phenyl, R 3 and R 4 are both methyl, R 5 and R 6 are both methyl, and R 7 and R 8 are both -H;
• R x and R 2 are both phenyl, R 3 and R 4 are both methyl, R 5 and R 6 are both methyl, and R 7 is -H and R 8 is methyl;
• R ⁇ and R 2 are both phenyl, R 3 and R 4 are both -H, R 5 and R 6 are both phenyl, R 7 is -H, and R 8 is methyl;
• R x and R 2 are the same or different; and/or R 3 and R 4 are the same or different; and/or R 5 and R 6 are the same or different.
• R x and R 2 are the same, R 3 and R 4 are the same and R 5 and R 6 are the same.
• a “straight chained hydrocarbyl group” is an alkylene group, i.e., -(CH 2 ) X -, with one or more (preferably one) internal methylene groups optionally replaced with a linkage group, x is a positive integer (e.g., between 1 and about 10), preferably between 1 and about 6 and more preferably 1 or 2.
• a “linkage group” refers to a functional group which replaces a methylene in a straight chained hydrocarbyl.
• linkage groups examples include a ketone (-C(O)-), alkene, alkyne, phenylene, ether (-O-), thioether (-S-), or amine [-N(R a )]- 5 wherein R a is defined below.
• a preferred linkage group is -C(R 7 R 8 )-, wherein R 7 and R 8 are defined above.
• Suitable substitutents for an alkylene group and a hydrocarbaryl group are those which do not substantially interfere with the anti-cancer activity of the disclosed compounds.
• R 7 and R 8 are preferred substituents for an alkylene or hydrocarbyl group represented by Y or Y' .
• An aliphatic group is a straight chained, branched or cyclic non-aromatic hydrocarbon which is completely saturated or which contains one or more units of unsaturation.
• a straight chained or branched aliphatic group has from 1 to about 20 carbon atoms, preferably from 1 to about 10, and a cyclic aliphatic group has from 3 to about 10 carbon atoms, preferably from 3 to about 8.
• An aliphatic group is preferably a straight chained or branched alkyl group, e.g, methyl, ethyl, n-propyl, -SO-propyl, n-butyl, -sec-butyl, tert-butyl, pentyl, hexyl, pentyl or octyl, or a cycloalkyl group with 3 to about 8 carbon atoms.
• a C1-C20 straight chained or branched alkyl group or a C3-C8 cyclic alkyl group is also referred to as a "lower alkyl" group.
• Aromatic groups include carbocyclic aromatic groups such as phenyl, naphthyl, and anthracyl, and heteroaryl groups such as imidazolyl, thienyl, furanyl, pyridyl, pyrimidy, pyranyl, pyrazolyl, pyrroyl, pyrazinyl, thiazole, oxazolyl, and tetrazole.
• Aromatic groups also include fused polycyclic aromatic ring systems in which a carbocyclic aromatic ring or heteroaryl ring is fused to one or more other heteroaryl rings.
• Examples include benzothienyl, benzofuranyl, indolyl, quinolinyl, benzothiazole, benzooxazole, benzimidazole, quinolinyl, isoquinolinyl and isoindolyl.
• arylene refers to an aryl group which is connected to the remainder of the molecule by two other bonds.
• 1,4-phenylene group is shown below:
• Non-aromatic heterocyclic rings are non-aromatic carbocyclic rings which include one or more heteroatoms such as nitrogen, oxygen or sulfur in the ring.
• the ring can be five, six, seven or eight-membered. Examples include tetrahydrofuranyl, tetrahyrothiophenyl, morpholino, thiomorpholino, pyrrolidinyl, piperazinyl, piperidinyl, and thiazolidinyl.
• Suitable substituents on an aliphatic group including an alkylene group), non-aromatic heterocyclic group, benzylic or aryl group (carbocyclic and heteroaryl) are those which do not substantially interfere with the anti-cancer activity of the disclosed compounds.
• a substituent substantially interferes with anti-cancer activity when the anti-cancer activity is reduced by more than about 50% in a compound with the substituent compared with a compound without the substituent.
• R a -R d are each independently an aliphatic, substituted aliphatic, benzyl, substituted benzyl, aryl or substituted aryl group, preferably an alkyl, benzylic or aryl group.
• -N(R a R b ), taken together, can also form a substituted or unsubstituted non-aromatic heterocyclic group.
• a non-aromatic heterocyclic group, benzylic group or aryl group can also have an aliphatic or substituted aliphatic group as a substituent.
• a substituted aliphatic group can also have a non-aromatic heterocyclic ring, a substituted a non-aromatic heterocyclic ring, benzyl, substituted benzyl, aryl or substituted aryl group as a substituent.
• a substituted aliphatic, non- aromatic heterocyclic group, substituted aryl, or substituted benzyl group can have more than one substituent.
• Examples of preferred substituents for the groups represented by R a -R d and -N(R a R b ) taken together include amino, alkylamino, dialkylamino, aminocarbonyl, halogen, alkyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylaminocarbonyloxy, dialkylaminocarbonyloxy, alkoxy, nitro, cyano, carboxy, alkoxycarbonyl, alkylcarbonyl, hydroxy, haloalkoxy, or haloalkyl.
• Preferred substituents for a cycloalkyl group are alkyl groups, such as a methyl or ethyl group.
• pharmaceutically acceptable salts of the compounds described herein Compounds disclosed herein which possess a sufficiently acidic, a sufficiently basic, or both functional groups, and accordingly can react with any of a number of organic or inorganic bases, and inorganic and organic acids, to form a salt.
• Acids commonly employed to form acid addition salts from compounds with basic groups are inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, and the like, and organic acids such as j?-toluenesulfonic acid, methanesulfonic acid, oxalic acid, p- bromophenyl-sulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, acetic acid, and the like.
• inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, and the like
• organic acids such as j?-toluenesulfonic acid, methanesulfonic acid, oxalic acid, p- bromophenyl-sulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, acetic acid, and the like.
• salts include the sulfate, pyrosulfate, bisulfate, sulf ⁇ te, bisulfite, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, propionate, decanoate, caprylate, acrylate, formate, isobutyrate, caproate, heptanoate, propiolate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, butyne-l,4-dioate, hexyne-l,6-dioate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phthalate, sulfonate, xylenesulfonate, phenylacetate, phenylpropionate, pheny
• Base addition salts include those derived from inorganic bases, such as ammonium or alkali or alkaline earth metal hydroxides, carbonates, bicarbonates, and the like.
• bases useful in preparing the salts of this invention thus include sodium hydroxide, potassium hydroxide, ammonium hydroxide, potassium carbonate, and the like.
• a "subject” is a mammal, preferably a human, but can also be an animal in need of veterinary treatment, e.g., companion animals (e.g., dogs, cats, and the like), farm animals (e.g., cows, sheep, pigs, horses, and the like) and laboratory animals (e.g., rats, mice, guinea pigs, and the like).
• companion animals e.g., dogs, cats, and the like
• farm animals e.g., cows, sheep, pigs, horses, and the like
• laboratory animals e.g., rats, mice, guinea pigs, and the like.
• Treating a subject with cancer includes achieving, partially or substantially, one or more of the following: arresting the growth or spread of a cancer, reducing the extent of a cancer (e.g., reducing size of a tumor or reducing the number of affected sites), inhibiting the growth rate of a cancer, and ameliorating or improving a clinical symptom or indicator associated with a cancer (such as tissue or serum components).
• Cancers that can be treated or prevented by the methods of the present invention include, but not limited to human sarcomas and carcinomas, e.g., fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, he
• leukemias include acute and/or chronic leukemias, e.g., lymphocytic leukemia (e.g., as exemplified by the p388 (murine) cell line), large granular lymphocytic leukemia, and lymphoblastic leukemia; T-cell leukemias, e.g., T-cell leukemia (e.g., as exemplified by the CEM, Jurkat, and HSB-2 (acute), YAC-1 (murine) cell lines), T-lymphocytic leukemia, and T-lymphoblastic leukemia; B cell leukemia (e.g., as exemplified by the SB (acute) cell line) , and B-lymphocytic leukemia; mixed cell leukemias, e.g., B and T cell leukemia and B and T lymphocytic leukemia; myeloid leukemias, e.g., granulocy
• the disclosed method is believed to be particularly effective in treating subject with non-solid tumors such as multiple myeloma.
• the disclosed method is believed to be particularly effective against T-leukemia (e.g., as exemplified by Jurkat and CEM cell lines); B-leukemia (e.g., as exemplified by the SB cell line); promyelocytes (e.g., as exemplified by the HL-60 cell line); uterine sarcoma (e.g., as exemplified by the MES-SA cell line); monocytic leukemia (e.g., as exemplified by the THP-1 (acute) cell line); and lymphoma (e.g., as exemplified by the U937 cell line); most preferably, this embodiment of the method employs Compound (1).
• the disclosed method is particularly effective at treating subjects whose cancer has become "multi-drug resistant".
• a cancer which initially responded to an anti-cancer drug becomes resistant to the anti-cancer drug when the anti-cancer drug is no longer effective in treating the subject with the cancer.
• many tumors will initially respond to treatment with an anti-cancer drug by decreasing in size or even going into remission, only to develop resistance to the drug.
• Drug resistant tumors are characterized by a resumption of their growth and/or reappearance after having seemingly gone into remission, despite the administration of increased dosages of the anti-cancer drug.
• Cancers that have developed resistance to two or more anti-cancer drugs are said to be "multi-drug resistant". For example, it is common for cancers to become resistant to three or more anti-cancer agents, often five or more anti-cancer agents and at times ten or more anti-cancer agents.
• an “effective amount” is the quantity of compound in which a beneficial clinical outcome is achieved when the compound is administered to a subject with a cancer.
• a “beneficial clinical outcome” includes a reduction in tumor mass, a reduction in metastasis, a reduction in the severity of the symptoms associated with the cancer and/or an increase in the longevity of the subject compared with the absence of the treatment.
• the precise amount of compound administered to a subject will depend on the type and severity of the disease or condition and on the characteristics of the subject, such as general health, age, sex, body weight and tolerance to drugs. It will also depend on the degree, severity and type of cancer. The skilled artisan will be able to determine appropriate dosages depending on these and other factors. Effective amounts of the disclosed compounds typically range between about 1 mg/mm 2 per day and about 10 grams/mm 2 per day, and preferably between 10 mg/mm 2 per day and about 5 grams/mm 2 .
• the disclosed compounds are administered by any suitable route, including, for example, orally in capsules, suspensions or tablets or by parenteral administration.
• Parenteral administration can include, for example, systemic administration, such as by intramuscular, intravenous, subcutaneous, or intraperitoneal injection.
• the compounds can also be administered orally (e.g., dietary), topically, by inhalation (e.g., intrabronchial, intranasal, oral inhalation or intranasal drops), or rectally, depending on the type of cancer to be treated.
• Oral or parenteral administration are preferred modes of administration.
• the disclosed compounds can be administered to the subject in conjunction with an acceptable pharmaceutical carrier as part of a pharmaceutical composition for treatment of cancer.
• Formulation of the compound to be administered will vary according to the route of administration selected (e.g., solution, emulsion, capsule).
• Suitable pharmaceutical carriers may contain inert ingredients which do not interact with the compound. Standard pharmaceutical formulation techniques can be employed, such as those described in Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, PA.
• Suitable pharmaceutical carriers for parenteral administration include, for example, sterile water, physiological saline, bacteriostatic saline (saline containing about 0.9% mg/ml benzyl alcohol), phosphate-buffered saline, Hank's solution, Ringer's-lactate and the like.
• compositions such as in a coating of hard gelatin or cyclodextrasn
• Methods for encapsulating compositions are known in the art (Baker, et al, "Controlled Release of Biological Active Agents", John Wiley and Sons, 1986).
• the disclosed compounds can be co-administered with other anti- cancer agents such as Adriamycin, Dactinomycin, Bleomycin, Vinblastine, Cisplatin, acivicin; aclarubicin; acodazole hydrochloride; acronine; adozelesin; aldesleukin; altretamine; ambomycin; ametantrone acetate; aminoglutethimide; amsacrine; anastrozole; anthramycin; asparaginase; asperlin; azacitidine; azetepa; azotomycin; batimastat; benzodepa; bicalutamide; bisantrene hydrochloride; bisnafide dimesylate; bizelesin; bleomycin sulfate; brequinar sodium; bropirimine; busulfan; cactinomycin; calusterone; caracemide; carbetimer; carboplatin,
• anti-cancer drugs include, but are not limited to: 20-epi-l,25 dihydroxyvitamin D3; 5-ethynyluracil; abiraterone; aclarubicin; acylfulvene; adecypenol; adozelesin; aldesleukin; ALL-TK antagonists; altretamine; ambamustine; amidox; amifostine; aminolevulinic acid; amrubicin; amsacrine; anagrelide; anastrozole; andrographolide; angiogenesis inhibitors; antagonist D; antagonist G; antarelix; anti-dorsalizing morphogenetic protein- 1; antiandrogen, prostatic carcinoma; antiestrogen; antineoplaston; antisense oligonucleotides; aphidicolin glycinate; apoptosis gene modulators; apoptosis regulators; apurinic acid; ara-CDP-DL-PT
• CARN 700 cartilage derived inhibitor; carzelesin; casein kinase inhibitors (ICOS); castanospermine; cecropin B; cetrorelix; chlorlns; chloroquinoxaline sulfonamide; cicaprost; cis-porphyrin; cladribine; clomifene analogues; clotrimazole; collismycin A; collismycin B; combretastatin A4; combretastatin analogue; conagenin; crambescidin 816; crisnatol; cryptophycin 8; cryptophycin A derivatives; curacin A; cyclopentanthraquinones; cycloplatam; cypemycin; cytarabine ocfosfate; cytolytic factor; cytostatin; dacliximab; decitabine; dehydrodidemnin B; deslorelin; dexa
• therapeutic antibodies examples include but are not limited to HERCEPTIN® (Trastuzumab) (Genentech, CA) which is a humanized anti-HER2 monoclonal antibody for the treatment of patients with metastatic breast cancer; REOPRO® (abciximab) (Centocor) which is an anti-glycoprotein Ilb/IIIa receptor on the platelets for the prevention of clot formation; ZENAPAX® (daclizumab) (Roche Pharmaceuticals, Switzerland) which is an immunosuppressive, humanized anti-CD25 monoclonal antibody for the prevention of acute renal allograft rejection; PANOREXTM which is a murine anti-17-IA cell surface antigen IgG2a antibody (Glaxo Wellcome/Centocor); BEC2 which is a murine anti-idiotype (GD3 epitope) IgG antibody (ImClone System); IMC-C225 which is a chimeric anti- EGFR IgG antibody (I
• Chemotherapeutic agents that can be used in the methods and compositions of the invention include but are not limited to alkylating agents, antimetabolites, natural products, or hormones.
• alkylating agents useful for the treatment or prevention of T-cell malignancies in the methods and compositions of the invention include but are not limited to, nitrogen mustards (e.g. , mechloroethamine, cyclophosphamide, chlorambucil, etc.), alkyl sulfonates (e.g., busulfan), nitrosoureas (e.g., carmustine, lomusitne, etc.), or triazenes (decarbazine, etc.).
• nitrogen mustards e.g. , mechloroethamine, cyclophosphamide, chlorambucil, etc.
• alkyl sulfonates e.g., busulfan
• nitrosoureas e.g., carmustine, lomusit
• antimetabolites useful for the treatment or prevention of T-cell malignancies in the methods and compositions of the invention include but are not limited to folic acid analog (e.g., methotrexate), or pyrimidine analogs (e.g., Cytarabine), purine analogs (e.g., mercaptopurine, thioguanine, pentostatin).
• folic acid analog e.g., methotrexate
• pyrimidine analogs e.g., Cytarabine
• purine analogs e.g., mercaptopurine, thioguanine, pentostatin
• Examples of natural products useful for the treatment or prevention of T-cell malignancies in the methods and compositions of the invention include but are not limited to vinca alkaloids (e.g., vinblastin, vincristine), epipodophyllotoxins (e.g., etoposide), antibiotics (e.g., daunorubicin, doxorubicin, bleomycin), enzymes (e.g., L-asparaginase), or biological response modifiers (e.g., interferon alpha).
• vinca alkaloids e.g., vinblastin, vincristine
• epipodophyllotoxins e.g., etoposide
• antibiotics e.g., daunorubicin, doxorubicin, bleomycin
• enzymes e.g., L-asparaginase
• biological response modifiers e.g., interferon alpha
• alkylating agents useful for the treatment or prevention of cancer in the methods and compositions of the invention include but are not limited to, nitrogen mustards (e.g., mechloroethamine, cyclophosphamide, chlorambucil, melphalan, etc.), ethylenimine and methylmelamines (e.g., hexamethlymelamine, thiotepa), alkyl sulfonates (e.g., busulfan), nitrosoureas (e.g., carmustine, lomusitne, semustine, streptozocin, etc.), or triazenes (decarbazine, etc.).
• nitrogen mustards e.g., mechloroethamine, cyclophosphamide, chlorambucil, melphalan, etc.
• ethylenimine and methylmelamines e.g., hexamethlymelamine, thiotepa
• antimetabolites useful for the treatment or prevention of cancer in the methods and compositions of the invention include but are not limited to folic acid analog (e.g., methotrexate), or pyrimidine analogs (e.g., fluorouracil, floxouridine, Cytarabine), purine analogs (e.g., mercaptopurine, thioguanine, pentostatin).
• folic acid analog e.g., methotrexate
• pyrimidine analogs e.g., fluorouracil, floxouridine, Cytarabine
• purine analogs e.g., mercaptopurine, thioguanine, pentostatin
• Examples of natural products useful for the treatment or prevention of cancer in the methods and compositions of the invention include but are not limited to vinca alkaloids (e.g., vinblastin, vincristine), epipodophyllotoxins (e.g., etoposide, teniposide), antibiotics (e.g., actinomycin D, daunorubicin, doxorubicin, bleomycin, plicamycin, mitomycin), enzymes (e.g., L-asparaginase), or biological response modifiers (e.g., interferon alpha).
• vinca alkaloids e.g., vinblastin, vincristine
• epipodophyllotoxins e.g., etoposide, teniposide
• antibiotics e.g., actinomycin D, daunorubicin, doxorubicin, bleomycin, plicamycin, mitomycin
• enzymes e.g., L-asparagina
• hormones and antagonists useful for the treatment or prevention of cancer in the methods and compositions of the invention include but are not limited to adrenocorticosteroids (e.g., prednisone), progestins (e.g., hydroxyprogesterone caproate, megestrol acetate, medroxyprogesterone acetate), estrogens (e.g., diethlystilbestrol, ethinyl estradiol), antiestrogen (e.g., tamoxifen), androgens (e.g., testosterone propionate, fluoxymesterone), antiandrogen (e.g., flutamide), gonadotropin releasing hormone analog (e.g., leuprolide).
• adrenocorticosteroids e.g., prednisone
• progestins e.g., hydroxyprogesterone caproate, megestrol acetate, medroxyprogesterone acetate
• platinum coordination complexes e.g., cisplatin, carboblatin
• anthracenedione e.g., mitoxantrone
• substituted urea e.g., hydroxyurea
• methyl hydrazine derivative e.g., procarbazine
• adrenocortical suppressant e.g., mitotane, aminoglutethimide
• the compounds disclosed herein are believed to be particularly effective when co-administered with anti-cancer agents which act by arresting cells in the G2- M phases due to stabilized microtubules.
• the disclosed method preferably includes co-administered anti-cancer drugs which act by this mechanism.
• taxol and analogs of taxol are excluded from the present invention unless a multidrug resistant cancer is being treated.
• Eleutherobins such as Desmethyleleutherobin, Desaetyleleutherobin, Isoeleutherobin A, and Z-Eleutherobin
• Caribaeoside Caribaeolin, Halichondrin B, D-64131 (Asta Medica), D-68144 (Asta Medica), Diazonamide A, A-293620 (Abbott), NPI-2350 (Nereus), Taccalonolide A, TUB-245 (Aventis), A-259754 (Abbott), Diozostatin, (-)- Phenylahistin (also known as NSCL-96F037), D-68838 (Asta Medica), D-68836 (Asta Medica), Myoseverin B, D-43411 (Zentaris, also known as D-81862), A- 289099 (Abbott), A-318315 (Abbott), HTI-286 (also known as SPA-110, trifluoroacetate salt
• Taxol also referred to as "Paclitaxel” is a well-known anti-cancer drug which acts by inhibiting microtubule formation.
• Many analogs of taxol are known, including taxotere, which is also referred to as ""Docetaxol”.
• Other taxol analogs are disclosed in the co-pending U.S. Serial Nos. 10/193,075 and 10/193,639, both entitled TAXOL ENHANCER COMPOUNDS and both filed July 10, 2002, the entire teachings of which are incorporated herein by reference.
• a "taxol analog” is defined herein to mean a compound which has the basic taxane skeleton and the ability to arrest cells in the G2-M phases due to stabilized microtubules.
• the basic taxane skeleton is shown below in Structural Formula (VII):
• Double bonds have been omitted from the cyclohexane rings in the taxane skeleton represented by Structural Formula (VII).
• the basic taxane skeleton can include zero or one double bond in one or both cyclohexane rings.
• substituents can decorate the taxane skeleton without adversely affecting biological activity.
• a number of atoms have also omitted from Structural Formula (VII) to indicate sites in which structural variation commonly occurs among taxol analogs. For example, substitution on the taxane skeleton with simply an oxygen atom indicates that hydroxyl, acyl, alkoxy or other oxygen-bearing substituent is commonly found at the site. It is to be understood that these and other substitutions on the taxane skeleton can also be made without losing the ability to enhance and stabilize microtubule formation.
• the disclosed compounds can be prepared according to methods described in Examples 1-14 and also according to methods described in the co-pending US serial No. 10/193,076, entitled SYNTHESIS OF TAXOL ENHANCERS, filed July 10, 2002. The entire teachings of this application are incorporated herein by reference.
• Phenyl hydrazine (5.4g, 50 mmol) was dissolved in dry dichloromethane (50 mL) in a 250 mL round bottom flask. Di-tert-butyl dicarbonate (10.9 g, 50 mmol) was then added with stirring at 0 °C. The resultant solution was then stirred under reflux for 3 h. Removal of the volatile components under reduced pressure afforded a colorless solid, which was washed with hexane and dried in vacuo. 10 g (yield 96%) of the product was obtained as a colorless solid, which can be used in the next step without further purification. 2.5 g (12 mmol) of this material was dissolved in dry pyridine (5 mL).
• N-phenyl-N-cyclohexyl-N'-tert-butoxycarbonylhydrazide 1.1 g, 3.46 mmol
• dichloromethane 6 mL
• trifluoroacetic acid 6 mL
• the resultant solution was stirred at 0 °C for half an hour.
• Volatile components were then removed under reduced pressure to afford a syrup, which was turned into a solid upon standing; this material was briefly mixed with cold 2 N NaOH (5 mL) for a few minutes at 0 °C.
• N-Malonyl-bis[N'-methyl-N'-(thiobenzoy hvdrazide] To a solution of thiobenzoic acid N-methylhydrazine (10 g) stirred at 0 C were added subsequently triethylamine (8.5 mL) and malonyl dichloride (3.05 mL). The reaction mixture was stirred for 10 min, washed with water (3x50 mL), dried over sodium sulfate and concentrated. Purification by recrystallization from methylene dichloride (35 mL) gave the product as light yellow crystals (9.0 g, 75%) which was identical to the product obtained in Example 6.
• Cyclopropyl bromide (4.8g, 40 mmol) was added into 50 ml anhydrous THF solution containing magnesium powder (l.lg, 45 mmol), stirred for 30 min, and refluxed for another 30 min. After it was cooled, the clear reaction solution was added into carbon disulfide (4 ml, 67 mmol) at 0 °C, and stirred for 30 min at rt. The resulting mixture was then added into methylhydrazine (8 ml, 150mmol) at 0 °C, and stirred for another 2 hours. To this solution was added water (40 ml) and extracted with EtOAc (60 ml x 3).
• the in vitro activity of the compounds was assessed in a selected set of human cancer cell lines. Three pairs of tumor cell lines (non-resistant/resistant) were used to identify novel potent antitumor compounds which are capable of overcoming multi-drug resistance.
• HL-60 a model of myeloid leukemia, was obtained from ATCC (ATCC
• HL-60/TX1000 was isolated in vitro by subculturing HL-60 in progressively higher concentration of Taxol.
• HL-60/TX1000 cells over-express mdr-1 mRNA and p-glycoprotein (PCP), as determined by western blot and immunofluorescence labeling with antiPGP antibodies. The cells are cross-resistant to Taxol, Vincristine, Adriamycin, Etoposide and Doxorubicin.
• MES-SA a model of uterine sarcoma, is sensitive to a number of chemotherapeutic agents, including Doxorubicin, Dactinomycin, Mitomycin C, Taxol and Bleomycin, but resistant to Vinblastine and Cisplatin.
• MES-SA /DX5 was established in the presence of increasing concentrations of Doxorubicin.
• the cells express high levels of mdr-1 mRNA and p-glycoprotein and exhibit cross resistance to more than fifteen chemotherapeutic agents including Taxol, Etoposide, Mitomycin C, Colchicine, Vinblastine, Dactinomycin, 5-Fluorouracil, Methotrexate and others.
• Both MES-SA and MES-SA Dx5 were purchased from ATCC (ATCC CRL-1976 and ATCC CRL-1977, respectively).
• Bowes is a melanoma cell line; and Bowes/OV2 is a Vincristine resistant Bowes melanoma cell line.
• the cell lines were maintained in RPMI1640 (GIBCO) supplemented with
• a stock solution of Compound (1), Taxol (positive control) and Vincristine (positive control) were prepared by dissolving the compound at a concentration of 1 mM in 100%) DMSO. Final concentrations were obtained by diluting the stock solution directly into the tissue culture medium. Cells were incubated with varying concentrations of compounds for 72 hours and the IC 50 was determined by MTS (i.e. 3-(4.5-dimethylthiazol-2-yl)-2.5-diphenyl tetrazolium bromide) assay. The IC 50 is the concentration of compound required to inhibit 50% tumor cell growth. The results are shown in Table 1.
• Taxol and Vincristine demonstrated significantly high anti-cancer activity (IC 50 : 0.002-0.005 uM) agaist normal cancer cell lines (MES-SA, HL-60, Bowes).
• these anti-cancer drugs were significantly less effective (IC 50 : 5 uM) against the MDR cell lines (MES-S A/DX5, HL-60/TX1000, Bowes/OV2).
• Compound (1) surprisingly showed higher anti-cancer activity against all three MDR cell lines.
• a supplemented media was prepared from 50% DMEM/Dulbecco Modified Eagle Medium (High Glucose), 50% RPMI 1640, 10% FBS/Fetal Bovine Serum (Hybridoma Tested; Sterile Filtered), 1% L-Glutamine, 1% Penicillin-Streptomycin, 1 % MEM Sodium Pyruvate and 1 % MEM Non-Essential Amino Acids.
• FBS was obtained from Sigma Chemical Co. and other ingredients were obtained from Invitrogen Life Technologies, USA).
• the supplemental media was warmed " to 37 °C and 50 ml of media was added to a 175 cm 2 tissue culture flask.
• the cells used in the assay were multi-drug resistant MES-SA/DX-5 Human Uterine Sarcoma cells from the American Type Culture Collection.
• 1 vial of MES- SA/DX-5 cells from the liquid nitrogen frozen cell stock was removed.
• the frozen vial of cells was immediately placed into a 37 °C water bath and gently swirled until thawed.
• the freeze-vial was wiped with 70% ethanol and cells were immediately pipetted into the 175 cm 2 tissue culture flask containing supplemented media.
• the cells were incubated overnight and the media was removed and replaced with fresh supplemented media the next day.
• the flask was incubated until the cells became about 90% confluent. This took anywhere from 5-7 days.
• the flask was washed with 10 ml of sterile room temperature phosphate buffered saline (PBS).
• the cells were trypsinized by adding 5 ml of warmed Trypsin-EDTA (Invitrogen) to the flask of cells. The cells were then incubated for 2-3 minutes at 37 °C until cells begun to detach from the surface of the flask. An equal volume of supplemented media (5 ml) was added to the flask. All the cells were collected into 50 ml tube, and centrifuged at 1000 RPM for 5 minutes at 20° C. The supernatant was aspirated and the cell pellet was resuspended in 10 ml of supplemented media and the cells were counted.
• PBS sterile room temperature phosphate buffered saline
• the above procedure for trypsinizing and centrifuging the cells were followed.
• the supernatant was aspirated and the cell pellet was resuspended in 10 ml of sterile PBS and the cells were counted.
• the cells were centrifuged and then resuspended with appropriate volume of sterile PBS for injection of correct number of cells needed for tumor implantation.
• 100 million cells were suspended with 2.0 ml of sterile PBS to a final concentration of 50 million cells/ml in order to inject 5 million cells in 0.1 ml/mouse.
• mice Five million MES-SA/DX5 cells were injected subcutaneously into the flan (lateral side) of female CB.17/SCID mice (Age 6-7 wks). These mice were obtained from Taconic, Germantown, NY. (Nomenclature: C.B-Zgb- ⁇ crTac-Pr :* ⁇ ) CB.17/SCID (FOX CHASE SCID) and are homozygous for the autosomal recessive scid (severe combined immunodeficient) gene and lack both T and B cells due to a defect in V(D)J recombination. Therefore, they easily accept foreign tissue transplants.
• tumors were allowed to grow until they reached a size of about 200-300 mm 3 before they were excised and prepared as a single cell suspension. These cells were then seeded into tissue culture flasks. The cells went through two passages in vitro before the tumor cells were collected.
• mice (CD-I nu/nu) were obtained from Charles River Laboratories: nomenclature: Crl:CD-l-nuBR, Age: 6-8 weeks. The mice were allowed to acclimate for 1 week prior to their being used in an experimental procedure.
• Implantation of the MES-SA/DX5 tumor cell suspension took place in the lateral flank of the female CD-I nu/nu mouse. Five million tumor cells in 0.1 mL of PBS were injected using a 27G (1/2 inch) needle. MES-SA DX5 tumors developed after 2-3 weeks after implantation.
• Compound stock solutions were prepared by dissolving the compound in cell- culture-grade DMSO (dimethyl sulf oxide) at the desired concentration. This stock solution in DMSO was sonicated in an ultrasonic water bath until all the powder dissolved.
• the Formulation Solvent was prepared as follows: 20% of Cremophore RH40
• Dosing Solution for Compound Administration The compound stock solution was diluted 1:10 with 20% Cremophore RH40: 1) 2.0 ml of 10 mg/ml dosing solution of Compound (16) was prepared by diluting 100 mg/ml Compound Stock solution with 1.8 ml of 20 % Cremophore RH40 water solution. The final formulation for the dosing solution was 10% DMSO, 18% Cremophore RH40 and 72% water.
• PROCEDURE A supplemented media was prepared from 50% DMEM/Dulbecco Modified Eagle Medium (High Glucose), 50% RPMI 1640, 10% FBS/Fetal Bovine Serum (Hybridoma Tested; Sterile Filtered), 1% L-Glutamine, 1% Penicillin-Streptomycin, 1% MEM Sodium Pyruvate and 1% MEM Non-Essential Amino Acids.
• FBS was obtained from Sigma Chemical Co. and other ingredients were obtained from
• the supplemental media was warmed to 37 °C and 50 ml of media was added to a 175 cm 2 tissue culture flask.
• the cells used in the assay were MDA-435 Human Breast Carcinoma from the American Type Culture Collection. 1 vial of MDA-435 cells from the liquid nitrogen frozen cell stock was removed. The frozen vial of cells was immediately placed into a 37 °C water bath and gently swirled until thawed. The freeze-vial was wiped with 70%) ethanol and cells were immediately pipetted into the 175 cm 2 tissue culture flask containing supplemented media. The cells were incubated overnight and the media was removed and replaced with fresh supplemented media the next day. The flask was incubated until flask became about 90% confluent. This took anywhere from 5-7 days.
• the flask was washed with 10 ml of sterile room temperature phosphate buffered saline (PBS).
• the cells were trypsinized by adding 5 ml of warmed Trypsin-EDTA (Invitrogen) to the flask of cells. The cells were then incubated for 2-3 minutes at 37 °C until cells begun to detach from the surface of the flask. An equal volume of supplemented media (5 ml) was added to the flask. All the cells were collected into 50 ml tube, and centrifuged at 1000 RPM for 5 minutes at 20° C. The supernatant was aspirated and the cell pellet was resuspended in 10 ml of supplemented media and the cells were counted.
• PBS sterile room temperature phosphate buffered saline
• MDA-435 tumor cell suspension took place into the corpus adiposum of the female CD-I nu/nu mouse. This fat body is located in the ventral abdominal viscera of the mouse. Tumor cells were implanted subsutaneously into the fat body located in the right quadrant of the abdomen at the juncture of the os coxae (pelvic bone) and the os femoris (femur). 5 million MDA-435 cells in 0.1 ml of sterile PBS were injected using 27 G (1/2 inch) needle. MDA-435 tumors developed 2-3 weeks after implantation. Compound stock solutions were prepared by dissolving the compound in cell- culture-grade DMSO (dimethyl sulfoxide) at the desired concentration. This stock solution in DMSO was sonicated in an ultrasonic water bath until all the powder dissolved.
• DMSO dimethyl sulfoxide
• the Formulation Solvent was prepared as follows: 20% of Cremophore RH40 (Polyoxyl 40 Hydrogenated Castor Oil obtained from BASF corp.) in water was prepared by first heating 100 %> Cremophore RH40 in a water bath at 50-60 °C until it liquefied and became clear. 10 ml of the 100 % Cremophore RH40 aliquoted into a conical centrifuge tube containing 40 ml of sterile water (1 :5 dilution of Cremophore RH40). The 20% Cremophore RH40 solution was reheated until it became clear again, and mixed by inverting the tube several times. This 20 %
• Cremophore RH40 solution was stored at room temperature, and was kept for up to 3 months.
• the compound stock solution was diluted 1:10 with 20% Cremophore RH40: 1) 2.0 ml of 10 mg/ml dosing solution of Compound (1) was prepared by diluting 100 mg/ml Compound Stock solution with 1.8 ml of 20 % Cremophore RH40 water solution; and 2) a dosoing solution comprising 2.0 ml of 1 mg/ml of Epothilone D and 5 mg/ml of Compound (1) was obtained by mixing 0.1 ml of Compound (1) DMSO stock solution (50 mg/ml) and 0.1 ml of Epothilone D DMSO stock solution (10 mg/ml) and diluting with 1.8 ml of 20 % Cremophore RH40 water solution.
• the final formulation for the dosing solution was 10%) DMSO, 18% Cremophore RH40 and
• Figure 3 shows the effects of Compound (1) on enhancing anti-tumor activity of Epothilone D.
• Compound (1) significantly enhanced anti-tumor activity of Epothilone D on human breast tumor MDA-435 in nude mice.
• Figure 4 shows the effects of treatment of Epothilone D and the combination of Compound (1) and Epothilone D on the body weight of nude mice bearing MDA-435 human breast tumor.
• Compound (1) enhanced anti-tumor activity of Epothilone D without increasing toxicity.
• the in vitro activity of the compounds was determined in a selected set of human leukemia cell lines.
• CEM T-cell leukemia
• Jurkat T-cell leukemia
• K562 chronic myelocyte
• THP-1 monocyte
• SB B-cell leukemia
• U937 lymphoma
• H2 leukemia cell line was a gift from Harvard Medical School.
• the cell lines were maintained in RPMI1640(GIBCO) supplemented with
• FCS 100 units/ml penicillin, 100 ug/ml streptomycin, and 2 mM L-glutamine.
• the cells were split every third day and diluted to a concentration of 2 x 105 cells/mL one day before experiment. All experiments were performed on exponentially growing cell culture. Cell densities were 2.5 x 104 cells/mL in all experiments.
• Compound (1) was prepared by dissolving the compound at a concentration of 10 mM in 100% DMSO. Final concentrations 10, 1, 0.1, 0.01 and 0.001 ⁇ M were obtained by diluting the stock solution directly into the tissue culture medium. Cells were incubated with varying concentrations of compounds for 72 hours and the IC50 was determined by MTS (i.e. 3-(4.5.-dimethylthiazol-2-yl)-2.5-diphenyl tetrazolium bromide) assay. IC50 is the concentration of compound required to inhibit 50%) tumor cell growth. Table 3 shows the in vitro IC50 ( ⁇ M) cytotoxicity results of Compound (1) versus vincristin and taxol. Table 3: h vitro Cytotoxicity (IC50, ⁇ M) of Compound (1) versus Vincristin and Taxol
• Example 20 Compound 1 inhibits human T-cell leukemia growth (CEM cell line)
• CEM Human T-cell leukemia cell line, CEM, was obtained from American Type Culture Collection. Eight- week old female SCID mice were purchased from Charles Rive Laboratories (Wilmington, MA). FITC conjugated anti-human HLA- A,B,C was obtained from BD ParMingen (Cat # 32294X). ACK lysing buffer was obtained from BioWhittaker.
• CEM cells (1x10° cells in 100 ⁇ l saline) were implanted intravenously into female SCID mice through the tail vein.
• Vehicle and Compound (1) 25mg/kg were administrated intraperitoneally twice a day and total for 3 weeks.
• bloods were taken from mouse retro-orbital sinus at 33.
• Red blood cells were partially lyzed with ACK lysing buffer.
• the cells were stained with FITC conjugated anti-human HLA-A,B,C antibody for one hour at 4°C.
• FACS analysis was performed to quantitate the amount of CEM cells in the blood.
• White blood cells were gated for FACS analysis. The results showed that about 37.7%, 4.6% and 1.07% of CEM cells were detected in the white blood cells from vehicle treated, Compound (1) treated, and untreated group respectively (Table 4).

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Epidemiology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Indole Compounds (AREA)
• Furan Compounds (AREA)
• Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Priority Applications (8)

Applications Claiming Priority (2)

Publications (1)

Family

ID=32771813

Family Applications (1)

Country Status (14)

Cited By (29)

Families Citing this family (13)

Citations (2)

Family Cites Families (67)

• 2004
  • 2004-01-14 TW TW093100878A patent/TWI330079B/zh not_active IP Right Cessation
  • 2004-01-15 JP JP2006500976A patent/JP4852409B2/ja not_active Expired - Fee Related
  • 2004-01-15 WO PCT/US2004/001089 patent/WO2004064826A1/en active IP Right Grant
  • 2004-01-15 DE DE602004002087T patent/DE602004002087T2/de not_active Expired - Lifetime
  • 2004-01-15 AU AU2004206865A patent/AU2004206865B2/en not_active Ceased
  • 2004-01-15 ES ES04702560T patent/ES2271839T3/es not_active Expired - Lifetime
  • 2004-01-15 US US10/758,589 patent/US7763658B2/en not_active Expired - Fee Related
  • 2004-01-15 DK DK04702560T patent/DK1583524T3/da active
  • 2004-01-15 AT AT04702560T patent/ATE336991T1/de active
  • 2004-01-15 EP EP04702560A patent/EP1583524B1/en not_active Expired - Lifetime
  • 2004-01-15 CA CA2512797A patent/CA2512797C/en not_active Expired - Fee Related
  • 2004-01-15 PT PT04702560T patent/PT1583524E/pt unknown
• 2006
  • 2006-04-07 HK HK06104252A patent/HK1084024A1/xx not_active IP Right Cessation
  • 2006-11-16 CY CY20061101668T patent/CY1106246T1/el unknown

Patent Citations (2)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events